A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : NOS-I

Search Conditions:
Search Keyword : NOS-I
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: NOS-I
Appearance Frequency: 89 time(s)
Long forms: 7

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
nitric oxide synthase
(75 times)
Neurology
(12 times)
NO (21 times)
NOS (5 times)
RVLM (4 times)
1994 Upregulation of neuronal nitric oxide synthase and mRNA, and selective sparing of nitric oxide synthase-containing neurons after focal cerebral ischemia in rat.
nitric oxide synthase type I
(6 times)
Neurology
(5 times)
NO (4 times)
ALS (1 time)
CaM-PDE (1 time)
1994 Co-localization of nitric oxide synthase and NGF receptor in neurons in the medial septal and diagonal band nuclei of the rat.
nitric oxide synthase inhibition
(3 times)
Cardiology
(1 time)
ASA (2 times)
ND (2 times)
BP (1 time)
2010 Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans.
neuronal isoform
(2 times)
Histocytochemistry
(1 time)
NO (2 times)
cGMP (1 time)
CO (1 time)
1996 Nitric oxide synthase I immunoreactivity and NOS-associated NADPHd histochemistry in the visceral epithelial cells of the intraplacental mouse yolk sac.
nitric oxide synthase-immunoreactive
(1 time)
Brain
(1 time)
ASL-I (1 time)
ASS-I (1 time)
NO (1 time)
1997 Morphologic evidence for L-citrulline conversion to L-arginine via the argininosuccinate pathway in porcine cerebral perivascular nerves.
NOS inhibited
(1 time)
Cardiology
(1 time)
CVC (1 time)
HT (1 time)
MAP (1 time)
2007 Local ascorbate administration augments NO- and non-NO-dependent reflex cutaneous vasodilation in hypertensive humans.
NOS isoform
(1 time)
Chemistry
(1 time)
CoMFA (1 time)
CoMSIA (1 time)
NO (1 time)
2002 Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors.